BNP Paribas Financial Markets Grows Position in VanEck Pharmaceutical ETF $PPH

BNP Paribas Financial Markets increased its position in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH) by 176.2% in the fourth quarter, Holdings Channel.com reports. The firm owned 300,000 shares of the company’s stock after purchasing an additional 191,371 shares during the quarter. BNP Paribas Financial Markets’ holdings in VanEck Pharmaceutical ETF were worth $30,951,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in PPH. Citigroup Inc. lifted its holdings in VanEck Pharmaceutical ETF by 987.8% during the 3rd quarter. Citigroup Inc. now owns 718,199 shares of the company’s stock valued at $64,896,000 after buying an additional 652,175 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in VanEck Pharmaceutical ETF by 0.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 256,985 shares of the company’s stock valued at $23,221,000 after buying an additional 1,148 shares in the last quarter. Revere Asset Management Inc bought a new stake in VanEck Pharmaceutical ETF during the 3rd quarter valued at about $15,628,000. Adamsbrown Wealth Consultants LLC lifted its holdings in VanEck Pharmaceutical ETF by 4.5% during the 4th quarter. Adamsbrown Wealth Consultants LLC now owns 143,045 shares of the company’s stock valued at $14,758,000 after buying an additional 6,146 shares in the last quarter. Finally, UBS Group AG lifted its holdings in VanEck Pharmaceutical ETF by 145.8% during the 4th quarter. UBS Group AG now owns 107,379 shares of the company’s stock valued at $11,078,000 after buying an additional 63,692 shares in the last quarter.

VanEck Pharmaceutical ETF Price Performance

Shares of PPH opened at $105.02 on Friday. VanEck Pharmaceutical ETF has a 1-year low of $81.74 and a 1-year high of $112.58. The firm has a market capitalization of $996.64 million, a price-to-earnings ratio of 20.21 and a beta of 0.47. The company has a 50-day moving average of $102.62 and a 200 day moving average of $104.11.

VanEck Pharmaceutical ETF Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, April 7th. Stockholders of record on Wednesday, April 1st were issued a $0.8441 dividend. The ex-dividend date was Wednesday, April 1st. This represents a $3.38 annualized dividend and a dividend yield of 3.2%. This is an increase from VanEck Pharmaceutical ETF’s previous quarterly dividend of $0.31.

VanEck Pharmaceutical ETF Company Profile

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.